The GLP-1 medication market is seeing significant changes, including FDA approval of oral weight loss drugs and expanded Medicare coverage starting in July 2024. These shifts could make weight loss medications more accessible to patients.
Posts tagged as “policy and regulation”
The growing peptide market is creating competition for brand-name GLP-1 drugs as compounding pharmacies offer alternatives to expensive medications. This trend is causing tension between commercial drug companies and compounding pharmacies over patient access to weight loss treatments.
The market for GLP-1 medications is expected to expand through 2034, driven by rising diabetes cases and new drug delivery methods. However, high costs and regulatory challenges remain barriers to wider patient access.
The FDA is proposing new rules that would permanently prevent specialty pharmacies from making their own versions of popular GLP-1 drugs like semaglutide and tirzepatide.
Health Canada has approved the first generic version of Ozempic, made by Dr Reddy's Laboratories, which could provide a lower-cost alternative to the popular diabetes medication. This approval marks increased competition in the growing GLP-1 drug market.
Changes in peptide regulations under RFK Jr.'s health policy could impact companies like Hims & Hers that offer GLP-1 medications online. The FDA review scheduled for 2026 will shape opportunities for these telehealth weight loss services.